Utama › Leukemia-Limfoma Limfoblastik Sel-T Pendahulu
Kajian klinikal Leukemia-Limfoma Limfoblastik Sel-T Pendahulu sedang mengambil peserta di AS
23 kajian untuk Leukemia-Limfoma Limfoblastik Sel-T Pendahulu sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Houston, TX8 kajian
- New York City, NY6 kajian
- Columbus, OH5 kajian
- Philadelphia, PA4 kajian
- Washington, DC4 kajian
- St. Louis, MO3 kajian
- Baldwin Park, CA3 kajian
- Boston, MA3 kajian
- East Norwalk, CT3 kajian
- New Rochelle, NY3 kajian
- Staten Island, NY3 kajian
- Queens, NY3 kajian
- Edison, NJ3 kajian
Mengikut negeri
- California5 kajian
- Colorado3 kajian
- Florida3 kajian
- Massachusetts3 kajian
- Missouri3 kajian
- New Jersey3 kajian
- New York7 kajian
- North Carolina3 kajian
- Ohio6 kajian
- Pennsylvania5 kajian
- Tennessee3 kajian
- Texas8 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Mengambil pesertaFasa 1
Umur 18 hingga 120 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06904066A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Mengambil pesertaFasa 2
6 Months · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06514794Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT04301076Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT01087333A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
Mengambil pesertaFasa 2
1 Month – 21 Years · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06561074Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT05289687Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Mengambil pesertaFasa 1
Sehingga umur 39 · Semua jantina · Dikemas kini 11 Sep 2026 · NCT04972942Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
Mengambil pesertaFasa 1
Umur 12 hingga 30 · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT07513129Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Mengambil pesertaFasa 1
Sehingga umur 75 · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT03081910Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Mengambil pesertaFasa 2
Umur 1 hingga 18 · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT06390319Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Mengambil pesertaFasa 2
Semua umur · Semua jantina · Dikemas kini 15 Jul 2026 · NCT00501826Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Mengambil pesertaFasa 1
Umur 0 hingga 29 · Semua jantina · Dikemas kini 7 Jul 2026 · NCT06934382Registry of Older Patients With Cancer
Mengambil pesertaKajian pemerhatian
Umur 65 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT01137825A Registry for People With T-cell Lymphoma
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 20 Mei 2026 · NCT05978141CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Mengambil pesertaFasa 1
Sehingga umur 21 · Semua jantina · Dikemas kini 19 Mei 2026 · NCT04318678Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
Mengambil pesertaFasa 1
Sehingga umur 75 · Semua jantina · Dikemas kini 18 Mei 2026 · NCT07220993Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Apr 2026 · NCT07356245Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Apr 2026 · NCT05996185A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Mac 2026 · NCT06698003Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Feb 2026 · NCT04848064Two Step Haplo With Radiation Conditioning
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Okt 2025 · NCT05031897Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 120 · Semua jantina · Dikemas kini 27 Okt 2025 · NCT01137643Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Apr 2025 · NCT06462365Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.